Journals / Journal of Clinical Research in Pediatric Endocrinology / 2018 / Cilt: 10 - Sayı: 1

Could Alerting Physicians for Low Alkaline Phosphatase Levels Be Helpful in Early Diagnosis of Hypophosphatasia?

Pages
19–24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Implementing lab-specific ranges and alerting for low levels could prompt physicians to investigate for undiagnosed HPP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hypophosphatasia (HPP) is an inborn error of metabolism with significant morbidity and mortality.
📊
Key Findings & Data:Methods: Patients under age 18 years with low ALP levels were identified from biochemistry records over a period of 6 months.
💡
Conclusion & Impact:Implementing lab-specific ranges and alerting for low levels could prompt physicians to investigate for undiagnosed HPP.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Hypophosphatasia (HPP) is an inborn error of metabolism with significant morbidity and mortality. Its presentation is nonspecific leading to delayed or missed diagnosis. Low alkaline phosphatase (ALP) is a diagnostic test. Unlike high ALP, low level is commonly not flagged by laboratories as abnormal. A new treatment was shown to be effective in HPP. In this study we aimed to establish the frequency of low ALP levels requiring notification to physicians by the laboratory and also to describe the clinical manifestations of patients presenting with low ALP for a possible diagnosis of HPP. Methods: Patients under age 18 years with low ALP levels were identified from biochemistry records over a period of 6 months. Reference ranges were used as per the Associated Regional and University Pathologists Reference Laboratory (Utah, USA). Electronic results for patients with low levels were checked for flagging as abnormal/low ALP results. Charts of identified patients were reviewed. Presenting features were categorized under groups of disorders. Results: ALP levels were tested in 2890 patients. 702 had values less than 160 U/L. Of these patients, 226 (32%) had age/gender specific low ALP. None of the low ALP results was flagged as low. Twenty-one had more than one low reading and their charts were reviewed. Four patients in the neuromuscular and four in the miscellaneous group presented with features consistent with HPP despite these patients having no specific diagnoses. Conclusion: Laboratories do not alert physicians in cases with low ALP levels. A persistently low level in patients with unspecified diagnoses could be a key to diagnose HPP. Implementing lab-specific ranges and alerting for low levels could prompt physicians to investigate for undiagnosed HPP.

🔖

Cite This Article

DEEB, A., ELFATİH, A. (2018). Could Alerting Physicians for Low Alkaline Phosphatase Levels Be Helpful in Early Diagnosis of Hypophosphatasia?. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 10 - Sayı: 1, 19–24. https://ajindex.com/articles/198508

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Whyte MP. Hypophosphatasia. In: Glorieux FH, Jueppner H, Pettifor J, eds. Pediatric bone: biology and diseases. 3rd ed. San Diego, CA: Academic Press, 2012:771-794. Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev 2013;10(Suppl 2):380-388. Whyte MP. Hypophosphatasia: nature’s window on alkaline phosphatase function in humans. In: Bilezikian JP, Raisz LG, Martin TJ, eds. Principles of bone biology. 3rd ed. San Diego, CA: Academic Press, 2008:1573-1598. Mornet E. Tissue non-specific alkaline phosphatase gene mutations database. Uiversity of Versailles-Saint Quentin en Yvelines, France: SESEP Laboratory and the Human Molecular Genetics, 2006.
  2. Taketani T, Onigata K, Kobayashi H, Mushimoto Y, Fukuda S, Yamaguchi S. Clinical and genetic aspects of hypophosphatasia in Japanese patients. Arch Dis Child 2014;99:211-215.
  3. Collmann H, Mornet E, Gattenlöhner S, Beck C, Girschick H. Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst 2009;25:217-223.
  4. Cahill RA, Wenkert D, Perlman SA, Steele A, Coburn SP, McAlister WH, Mumm S, Whyte MP. Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. J Clin Endocrinol Metab 2007;92:2923-2930.
  5. Moulin P, Vaysse F, Bieth E, Mornet E, Gennero I, Dalicieux-Laurencin S, Baunin C, Tauber MT, De Gauzy JS, Salles JP. Hypophosphatasia may lead to bone fragility: don’t miss it. Eur J Pediatr 2009;168:783-788.
  6. Balasubramaniam S, Bowling F, Carpenter K, Earl J, Chaitow J, Pitt J, Mornet E, Sillence D, Ellaway C. Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5’-phosphate availability. J Inherit Metab Dis 2010;33:S25-33. Jenny C. Evaluating infants and young children with multiple fractures: Pediatrics 2006;118:1299-1303.
  7. Mohn A, De Leonibus C, de Giorgis T, Mornet E, Chiarelli F. Hypophosphatasia in a child with widened anterior fontanelle: lessons learned from late diagnosis and incorrect treatment. Acta Paediatr 2011;100:43-46.
  8. Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar AM, Crine P, Landy H. Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia. N Engl J Med 2012;366:904- 913. http://www.ema.europa.eu/ema/index.jsp?curl